Preface; PART I: Clinical aspects in coronary artery disease; 1. Metabolic syndrome, diabetes & CHD risk, C Byrne; 2. Use of novel risk factors in prevention and therapeutic strategies, N Sattar; 3. Diet & exercise in the prevention & treatment of CHD, J Tuomilehto; 4. Technologies for assessment of atherosclerotic burden in man, C Berry, J McMurray; PART II: Lipids, lipoproteins & atherosclerosis; 5. HDL structure & metabolism: its regulation by cell membrane receptors, K-A Rye; 6. Oxidative stress, LDL oxidation, and atherosclerosis, tbc; 7. Metabolism of apoB containing lipoproteins in dyslipidaemia, G Watts; 8. Sex specific aspects of dyslipidaemia and atherosclerosis; (dyslipidaemia in pre-eclampsia and in utero programming of CHD risk), tbc; PART III: Prevention and treatment strategies; 9. New clinical trials of lipid regulating agents, AG Olsson; 10. Genetics of dyslipidaemia & coronary risk; (personalised lipid lowering treatment), P Talmud; 11. The application of proteomic & lipidomic approaches to CHD risk prediction, F McTaggart; 12. New drug targets; nuclear receptors (PPARS, LXR, FXR) and their role in regulating lipid metabolism, A Catapano; PART IV: Infection, inflammation and secondary causes of atherosclerosis; 13. Inflammation, inflammatory disease, and atherosclerosis, R Rosensen; 14. Kidney disease, end stage renal failure & accelerated CHD, M Tonnelli; 15. Chronic infection(s) and lipids, M Bassendine; 16. Haemaeostasis, dyslipidemia interactions in CHD, GY Lip; List of abbreviations; Index of papers reviewed; General index.
